Fluorescence diagnosis using enzyme-related metabolic abnormalities of neoplasia

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 25, Issue 1-2, 2006, Pages 341-372

  Campo, Marino A ^a   Lange, Norbert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Aminolevulinic acid; Aminolevulinic acid derivatives; Cancer; Fluorescence diagnosis; HAL; Imaging; Metabolism; Proteases

Indexed keywords

AMINO ACID DERIVATIVE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; COPOLYMER; DIAGNOSTIC AGENT; MACROGOL; POLOXAMER; POLYACRYLIC ACID; POLYOXYETHYLENE DERIVATIVE; POLYSACCHARIDE; PORPHYRIN DERIVATIVE; PROTEINASE;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CHEMICAL MODIFICATION; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG SENSITIVITY; FLUORESCENCE; GLYCOLYSIS; HUMAN; IONTOPHORESIS; MEDICAL INSTRUMENTATION; METABOLIC DISORDER; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PATIENT CARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SKIN SENSITIZATION; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; TOMOGRAPHY;

EID: 33644769381     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.220     Document Type: Article

References (123)

1. Benaron, DA. The future of cancer imaging. Cancer Metastasis Rev 2002; 21:45-78.
2. Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH. 1999. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1999; 1:303-310.
3. Muvaffak A, Hasirci N. The use of antibodies in diagnosis and therapy of cancer. Adv Exp Med Biol 2003; 534:309-325.
4. Krauss J. Recombinant antibodies for the diagnosis and treatment of cancer. Mol Biotechnol 2003; 25:1-17.
5. Ruebi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev 2003; 24:389-427.
6. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenisis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380.
7. Cutler CS, Lewis JS, Anderson CJ. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Adv Drug Deliv Rev 1999; 37:189-212.
8. Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D. Vitamin-mediated targeting as potential mechanism to increase drug uptake by tumors. J Inorg Biochem 2004; 98:1625-1633.
9. Ke C-Y Matthias CJ. Folate-receptor-targeted radionucleotide imaging agents. Adv Drug Deliv Rev 2004; 56:1143-1160.
10. Katzenellenbogen, JA. The development of probes for fluorescence assay, tumor imaging, and structural studies of steroidal receptors. Med Chem Res 1995; 5:606-617.
11. Zheng, G, Zhang M, Li H, Chance B. Synthesis and biological evaluation of near infrared fluorescence probes (NIRFs) for tumors overexpressing LDL receptors. 223rd ACS National Meeting, Orlando, FL 2002. Abstract MEDI-220.
12. Ponty E, Favre G, Benaniba R, Boneu A, Lucot H, Carton M, Soula G. Biodistribution study of technetium-99m-labeled LDL in B16-melanoma-bearing mice. Visualization of a preferential uptake by the tumor. Int J Cancer 1993; 54:411-417.
13. Hutchinson OC, Collingridge DR, Barther H, Price PM, Aboagye EO. Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Des 2003; 9:931-944.
14. Wagnieres GA, Star WM, Wilson BC. In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem Photobiol 1998; 68:603-632.
15. Zimmern PE, Laub D, Leach GE. Fluorescein angiography of the bladder: technique and relevance to bladder cancer and interstitial cystitis patients. J Urol 1995; 154:62.
16. Whitmore WFJ, Bush IM. Ultraviolet cystoscopy. JAMA 1968; 203:1057-1059.
17. Stefanadis C, Chrysochoou C, Markou D, Petraki K, Panagiotakos DB, Fasoulakis C, Kyriakidis A, Papadimitriou C, Toutouzas PK. Related increased temperature of malignant urinary bladder tumors in vivo: the application of a new method based on a catheter technique. J Clin Oncol 2001; 19:676-681.
18. Mordon S, Devoisselle JM, Maunoury V. In vivo pH measurements and imaging of tumor tissue using a pH-sensitive fluorescence probe (5,6- carboxyfluorescein): instrumental and experimental studies. Photochem Photobiol 1994; 60:274-279.
19. Mordon S, Devoisselle JM, Soulie S. Fluorescence spectroscopy of pH in vivo using a dual-emission fluorophore (C-SNAFL-1). J Photochem Photobiol B 1995; 28:19-23.
20. Marechal X, Mordon S, Devoisselle JM, Begu S, Guery B, Neviere R, Buys B, Dhelin G, Lesage JC, Mathieu D, Chopin C. In vivo application of intestinal pH measurements using 2′,7′-bis(carboxyethyl)-5,6-carboxy-fluorescein (BCECF) fluorescence imaging. Photochem Photobiol 1999; 70:813-819.
21. Martin GR,Jain RK. Noninvasive measurements of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 1994; 54:5670-5674.
22. Helmlinger G, Yuan F, Dellian M, Jain RK. 1997. Interstitial pH and pO2 gradients in solid tumors in vivo: high resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177-182.
23. Weissleder R, Tung CH, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999; 17:375-378.
24. Bremer C, Tung C-H, Bogdanov A, Weissleder R. 2002. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 2002; 222:814-818.
25. Mahmood U, Tung C-H, Bogdanov A, Weissleder R. 1999. Near-infrared optical imaging of protease activity for tumor detection. Radiology 1999; 213:866-870.
26. Tung C-H, Bredow S, Mahmood U, Weissleder R. Preparation of cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug Chem 1999; 10:892-896.
27. Tung C-H, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 2000; 60:4953-4958.
28. Gulnik SV, Suvorov LI, Majer P, Collins J, KaneBP, Johnson JD, Erickson JW. Design of sensitive fluorogenic substrates for human cathepsin D. FEBS Lett 1997; 413:379-384.
29. Ren WP, Sloane BF. Cathepsins D and B in breast cancer. Cancer Treat Res 1996; 83:325-352.
30. Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch Dermatology 1998; 134:207-214.
31. Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnières G, Zimmer G, Guillou L, Schmidlin F, Graber P, Van den Bergh H, Leisinger HJ. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 1997; 402-408.
32. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstadter F, Hofstetter A. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994; 44:836-841.
33. Kriegmair M, Baumgartner R, Lumper W, Waidelich R, Hofstetter A. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Cancer 1996; 77:667-671.
34. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, Ell C. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114:448-455.
35. Mehlmann M, Betz CS, Stepp H, Arbogast S, Baumgartner R, Grevers G, Leunig A. Fluorescence staining of laryngeal neoplasms after topical application of 5-Aminolevulinic acid: Preliminary results. Lasers Surg Med 1999; 25:414-420.
36. Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 1996; 78:1374-1383.
37. Wyss P, Fehr M, Van den Bergh H, Haller U. Feasibility of photodynamic endometrial ablation without anesthesia. Int J Gynaecol Obstet 1998; 60:287-288.
38. Hillemanns P, Korell M, Schmitt-Sody M, Baumgartner R, Beyer W, Kimmig R, Untch M, Hepp H. Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Int J Cancer 1999; 81:34-38.
39. Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, Goetz AE, Kiefmann R, Reulen HJ. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42:518-525.
40. Jenkins MP, Buonaccorsi GA, Mansfield R, Bishop CC, Bown SG, McEwan JR. Reduction in the response to coronary and iliac artery injury with photodynamic therapy using 5-aminolaevulinic acid. Cardiovascular Res 2000; 45:478-485.
41. Mesenholler M, Matthews EK. A key role for the mitochondrial benzodiazepine receptor in cellular photosensitisation with delta- aminolaevulinic acid. Eur J Pharmacol 2000; 406:171-180.
42. Malik, Z, Lugaci H. 1987. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br J Cancer 1987; 56:589-595.
43. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6:143-148.
44. Collaud SC, Juzeniene A, Moan J, Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anti-Canc Agents 2004; 4:301-316.
45. Jacobs JB, Cohen, Farrow GM, Friedell GH. Scanning electron microscopic features of human urinary bladder cancer. Cancer 1981;48:1399-1409.
46. Stefanadis C, Chrysochoou C, Markou D, Petraki K, Panagiotakos DB, Fasoulakis C, Kyriakidis A, Papadimitriou C, Toutouzas PK. Related increased temperature of malignant urinary bladder tumors in vivo: the application of a new method based on a catheter technique. J Clin Oncol 2001; 19:676-681.
47. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79:2282-2308.
48. Marcus SL, Sobel RS, Golub AL, Carroll RL, Lundahl S, Shulman DG. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. J Clin Laser Med Surg 1996; 14:59-66.
49. Malik Z, Kostenich G, Roitman L, Ehrenberg B, Orenstein A. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J Photochem Photobiol B 1995; 28:213-218.
50. Sibourd-Baudry A. Photodetection de cancer bronchique a l'aide de l'acide aminolevulinique: pharmacocinétique et microscopie de fluorescence. Diploma Work University of Munich, 1998.
51. Vonarx V, Eleouet S, Carre J, Ioss P, Gouyette A, Leray AM, Merle C, Lajat Y, Patrice T. Potential efficacy of a delta 5-aminolevulinic acid bioadhesive gel formulation for the photodynamic treatment of lesions of the gastrointestinal tract in mice. J Pharm Pharmacol 1997; 49:652-656.
52. Baumgartner R, Huber RM, Schulz H, Stepp H, Rick K, Gamarra F, Leberig A, Roth C. Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J Photochem Photobiol B 1996; 36:169-174.
53. Huber RM, Gamarra F, Hautmann H, Häussinger K, Wagner D, Castro M, Baumgartner R. 5-Aminolevulinic acid (ALA) for the fluorescence detection of bronchial tumors. Diagnos Therapeut Endoscopy 1999; 5:113-118.
54. De Rosa FS, Marchetti JM, Thomazini JA, Tedesco AC, Bentley, MVLP. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release 2000; 65:359-366.
55. Marti A, Lange N, Van den Bergh H, Sedmera D, Jichlinski P, Kucera P. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol 1999; 162:546-552.
56. Berg K, Anholt H, Bech O, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer 1996; 74:688-697.
57. Orenstein A, Kostenich G, Tsur H, Roitman L, Ehrenberg B, Malik Z. Photodynamic therapy of human skin tumors using topical application of 5-aminolevulinic acid, DMSO and EDTA. Proc SPIE 1995; 2325:100-105.
58. Warloe T, Peng Q, Heyerdahl H, Moan J, Steen HB, Giercksky KE. Photodynamic therapy with 5-aminolevulinic acid-induced porphyrins and DMSO/EDTA for basal cell carcinoma. Proc SPIE 1995; 2371:226-235.
59. Chang SC, MacRobert AJ, Porter JB, Bown SG. The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. J Photochem Photobiol B 1997; 38:114-122.
60. Rebeiz N, Arkins S, Rebeiz CA, Simon J, Zachary JF, Kelley KW. Induction of tumor necrosis by delta-aminolevulinic acid and 1,10-phenanthroline photodynamic therapy. Cancer Res 1996; 56:339-344.
61. Rebeiz N, Rebeiz CC, Arkins S, Kelley KW, Rebeiz CA. Photodestruction of tumor cells by induction of endogenous accumulation of protoporphyrin IX: enhancement by 1,10-phenanthroline. Photochem Photobiol 1992; 55:431-435.
62. Fukuda H, Paredes S, Batlle AM. In vitro studies using the porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms. Drug Des Deliv 1989; 5:133-139.
63. Fukuda H, Paredes S, Batlle AM. Tumour-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid. Comp Biochem Physiol B 1992; 102:433-436.
64. Hurlimann AF, Hanggi G, Panizzon RG. Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 1998; 197:248-254.
65. Hillemanns P, Weingandt H, Baumgartner R, Diebold J, Xiang W, Stepp H. Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence. Cancer 2000; 88:2275-2282.
66. Rhodes LE, Tsoukas MM, Anderson RR, Kollias N. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J Invest Dermotol 1997; 108:87-91.
67. Stenzl A, Eder I, Kostron H, Klocker H, Bartsch G. Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolaevulinic acid (delta-ALA) for superficial bladder cancer. J Photochem Photobiol B 1996; 36:233-236.
68. Kloek J, Beijersbergen van Henegouwen BM. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol 1996; 64:994-1000.
69. Casas A, Batlle AM, Butler AR, Robertson D, Brown EH, MacRobert A, Riley PA. Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures. Br J Cancer 1999; 80:1525-1532.
70. Berger Y, Greppi A, Siri O, Neier O, Juillerat-Jeanneret L. Ethylene glycol and amino acid derivatives of 5-aminolevulinic acid as new photosensitizing precursors of protoporphyrin IX in cells. J Med Chem 2000; 43:4738-4746.
71. Uehlinger P, Zellweger M, Wagnières G, Juillerat-Jeanneret L, Van den Bergh H, Lange N. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B 2000; 54:72-80.
72. Gerscher S, Connelly JP, Griffiths J, Brown SB, MacRobert AJ, Wong G, Rhodes LE. Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo. Photochem Photobiol 2000; 72:569-574.
73. Van den Akker JT, Iani V, Star WM, Sterenborg HJ, Moan J. Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol 2000; 72:681-689.
74. Dögniz N, Salomon D, Ballini JP, Gabrecht T, Lange N, Van den Bergh H, Wagnières G. Comparison of ALA and ALA hexylester-induced PpIX depth distribution in human skin carcinoma (unpublished).
75. Lopez RF, Bentley MV, Delgado-Charro MB, Salomon D, van den Bergh H, Lange N, Guy RH. Enhanced delivery of 5-aminolevulinic acid esters by iontophoresis in vitro. Photochem Photobiol. 2003; 77(3):304-308.
76. Peng Q, Moan J, Warloe T, Iani V, Steen HB, Bjorseth A, Nesland JM. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 1996; 34:95-96.
77. Fritsch C, Stahl W, Lehmann P, Ruzicka T, Sies H, Homey B. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998; 68:218-221.
78. Rud E, Gederaas O, Hogset A, Berg K. 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 2000; 71:640-647.
79. Whitaker CJ, Battah SH, Forsyth MJ, Edwards C, Boyle RW, Matthews EK. Photosensitization of pancreatic tumour cells by delta-aminolaevulinic acid esters. Anticancer Drug Des 2000;15:161-170.
80. Gederaas OA, Holroyd A, Brown SB, Vernon D, Moan J, Berg K. 5-aminolevulinic acid methyl ester transport on amino acid carriers in a human colon adenocarcinoma cell line. Photochem Photobiol 2001;73:164-169.
81. Kloek J, Akkermans W, Beijersbergen van Henegouwen GM. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem Photobiol 1998; 67:150-159.
82. Eleouet S, Rousset N, Carre J, Bourre L, Vonarx V, Lajat Y, Beijersbergen van Henegouwen GM, Patrice T. In vitro fluorescence, toxicity and phototoxicity induced by delta-aminolevulinic acid (ALA) or ALA-esters. Photochem Photobiol 2000; 71:447-454.
83. Washbrook R, Riley PA. Comparison of delta-aminolaevulinic acid and its methyl ester as an inducer of porphyrin synthesis in cultured cells. Br J Cancer 1997; 75:1417-1420.
84. Gaullier JM, Berg K, Peng Q, Anholt A, Selbo PK, Ma LW, Moan J. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 1997; 57:1481-1486.
85. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, Kucera P, Wagnières G, Van den Bergh H. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1997; 80:185-193.
86. Lange N, Vaucher L, Marti A, Etter AL, Gerber P, Van den Bergh H, Jichlinski P, Kucera P. Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia. J Biomed Opt 2001; 62:151-159.
87. Barry BW. Dermatologic Formulation: Percutaneous Absorption, Drugs and Pharmaceutical Science. New York: Marcel Dekker, 1983.
88. Conder LH, Woodard SI, Dailey HA. Multiple mechanisms for the regulation of haem synthesis during erythroid cell differentiation. Possible role for coproporphyrinogen oxidase. Biochem J 1991; 275:321-326.
89. Malik Z, Djaldetti M. 5-Aminolevulinic acid stimulation of porphyrin and hemoglobin synthesis by uninduced Friend erythroleukemic cells. Cell Differ 1979; 8:223-233.
90. Jacob SW, Herschler R. Pharmacology of DMSO. Cryobiology 1986; 23:14-27.
91. Andikyan V, Kronschnabl M, Hillemanns M, Wang X, Stepp H, Hillemanns P. Fluorescence diagnosis with 5-ALA thermogel of cervical intraepithelial neoplasia. Gynakol Geburtshilfliche Rundsch 2004; 44:31-37.
92. Hinnen P, De Rooij FW, Van Velthuysen ML, Edixhoven A, Van Hillegersberg R, Tilanus HW, Wilson JH, Siersema PD. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the esophagus. Br J Cancer 1998; 78:679-682.
93. Messmann H. 5-Aminolevulinic acid-induced protoporphyrin IX for the detection of gastrointestinal dysplasia. Gastrointest Endosc Clin N Am 2000; 10:497-512.
94. Messmann H, Knuchel R, Baumler W, Holstege A, Scholmerich J. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization. Gastrointest Endosc 1999; 49:97-101.
95. Fuchs C, Riesenberg R, Siegert J, Baumgartner R. pH-dependent formation of 5-aminolaevulinic acid-induced protoporphyrin IX in fibrosarcoma cells. J Photochem Photobiol B 1997; 40:49-54.
96. Wyld L, Reed MW, Brown NJ. The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. Br J Cancer 1998; 77:1621-1627.
97. Banga AK, Bose S, Ghosh TK. Iontophoresis and electroporation: comparisons and contrasts. Int J Pharm 1999; 179:1-19.
98. Fotinos N, Popowycz F, Lange N. 5-Aminolevulinic acid derivatives in photomedicine: basics, application and perspectives (unpublished).
99. Van den Akker JTHM, De Bruijn HS, Beijersbergen van Henegouwen GMJ, Star WM, Sterenborg HJCM. Protoporphyrin IX fluorescence kinetics and localization after topical application of ALA pentyl ester and ALA on hairless mouse skin with UVB-induced early skin cancer. Photochem Photobiol 2000; 72:399-406.
100. Van den Akker JT, Iani V, Star WM, Sterenborg HJ, Moan J. Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol 2000; 72:681-689.
101. Juzeniene A, Juzenas P, Iani V, Moan J. Topical application of 5-aminolevulinic acid and its methylester, hexylester and octylester derivatives: considerations for dosimetry in mouse skin model. Photochem Photobiol 2002; 76:329-334.
102. Peng Q, Moan J, Warloe T, Iani V, Steen HB, Bjorseth A, Nesland JM. Build-up of esterified aminolevulinic acid derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 1996; 34:95-96.
103. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-aminolevulinic acid-based photodynamic therapy: principal and experimental research. Photochem Photobiol 1997; 65:235-251.
104. Fritsch C, Homey B, Atahl W, Lehmann P, Ruzicka T, Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998;68:218-221.
105. Collaud S, Lange N (unpublished).
106. Bigelow CE, Mitra S, Knuechel R, Foster TH. ALA- and ALA-hexylester- induced protoporphyrin IX fluorescence and distribution in multicell tumour spheroids. Br J Cancer 2001; 85:727-734.
107. Marti A, Lange N, Van den Bergh H, Sedmera D, Jichlinski P, Kucera P. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol 1999; 162:546-552.
108. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003; 170:428-432.
109. De Rosa FS, Tedesco AC, Lopez RF, Pierre MB, Lange N, Marchetti JM, Rotta JC, Bentley MV. In vitro skin permeation and retention of 5-aminolevulinic acid ester derivatives for photodynamic therapy. J Control Release 2003; 89:261-269.
110. Doring F, Walter J, Will J, Focking M, Boll M, Amasheh S, Clauss W, Daniel H. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest 1998; 101:2761-2767.
111. Fritsch C. Personal communication. 2005.
112. Jichlinski P, Aymon D, Wagnieres GA, Marti A, Lange N, Guillou L Leisinger HJ, van den Bergh H. On the influence of instillation time on the results of HAL fluorescence detection of superficial bladder cancer. SPIE 2003; 5141:272-277.
113. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003; 170:428-432.
114. Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, Johansson E, Gartner T, Lange N, Van den Bergh H, Leisinger HJ. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 2003; 170:226-229.
115. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171:135-138.
116. Durek C, Wagner S, Zeijlemaker B, van Moorselaar J, Witjes JA, Grimm MO, Muschter R, Popken G, Koenig F, Kurth KH, Knuechel R, Jocham D. The impact of Hexvix-based fluorescence cystoscopy in the treatment decisions of bladder cancer - results of a prospective phase III multicenter study. AUA Meeting San Francisco, 2004; Abstract 278.
117. Zaak D, Frimberger F, Stepp H, Wagner S, Baumgartner R, Schneede P, Siebels M, Knuchel R, Kriegmair M, Hofstetter A. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol 2001; 166:1665-1668
118. Ludicke F, Gabrecht T, Lange N, Wagnieres G, Van den Bergh H, Berclaz L, Major AL. Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: a preclinical study. Br J Cancer 2003; 88:1780-1784.
119. Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q. 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors. Int J Oncol 2002; 21:577-582.
120. Ntziachristos V, Tung C, Bremer C, Weissleder R. Fluorescence mediated tomography resolves protease activity in vivo. Nat Med 2001; 8:760.
121. Ntziachristos V, Ripoll J, Weissleder R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies. Opt Lett 2002; 27:527-529.
122. Manning HC, Goebel T, Thompson RC, Price RR, Lee H, Bornhop DJ. Targeted molecular imaging agents for cellular-scale bi-modal imaging. Bioconjug Chem 2004; 15:1488-1495.
123. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem 2002; 13:554-560.